Authors: Dana Tomčíková; Zuzana Prepiaková; Beáta Bušányová; Barbora Kostolná Authors‘ workplace: University and the National Institute of Children’s Diseases, Bratislava, Slovakia ; Department of Pediatric Ophthalmology, Faculty of Medicine of Comenius Published in: Čes. a slov. Oftal., 81, 2025, No. 6, p. 1-5 Category: Original Article doi: https://doi.org/10.31348/2025/23
Retinopathy of prematurity (ROP) is always a serious and sight-threatening condition, and its treatable stages require early detection and adequate treatment. It is necessary to focus on the principles of screening of ROP and recurrences thereof, which occur more often with the onset of intravitreal treatment using anti-vascular endothelial growth factor (anti-VEGF) agents. In this study, we evaluate the recurrence of ROP after primary treatment with intravitreally administered bevacizumab or ranibizumab, its frequency and timing of occurrence. Also discussed are the rules for screening of ROP, its recurrence and the need for long-term follow-up monitoring of children with any form of ROP.
recurrence of ROP – ROP recurrence screening – intravitreal treatment of ROP – follow-up monitoring of premature infants with ROP – ROP screening – ROP screening
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
